Monterey Innovation Acquisition Corp. Common Stock
Compare this stock
MTRY Stock Report Card
$
45%
Performance
Score:
100/100
MTRY returned 9.16% in the last 12 months. Based on SPY's performance of -2.40%, its performance is above average giving it a score of 100 of 100.
Profit
Score:
10/100
Out of the last 10 quarters, MTRY has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
67/100
MTRY has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.
Monterey Innovation Acquisition Corp. Common Stock Summary
Nasdaq / MTRY
Financial Services
Shell Companies
Monterey Bio Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp. and changed its name to Monterey Bio Acquisition Corporation in April 2021. Monterey Bio Acquisition Corporation was incorporated in 2020 and is based in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
MTRY scored poorly on our reportcard. Here are some similar companies and how they performed.
